01 5Androgel
02 1Androgel
03 2Axiron
04 2Testopel
05 2Tostran/Fortesta
Main Therapeutic Indication : Hormonal Disorders
Currency : USD
2017 Revenue in Millions : 577
2016 Revenue in Millions : 675
Growth (%) : -15
Main Therapeutic Indication : Hormonal Disorders
Currency : USD
2016 Revenue in Millions : 675
2015 Revenue in Millions : 694
Growth (%) : -3
Main Therapeutic Indication : Hormonal Disorders
Currency : USD
2015 Revenue in Millions : 934
2014 Revenue in Millions : 694
Growth (%) : -26%
Main Therapeutic Indication : Hormonal Disorders
Currency : USD
2018 Revenue in Millions : 469
2017 Revenue in Millions : 577
Growth (%) : -19%
Main Therapeutic Indication : Hormonal Disorders
Currency : USD
2019 Revenue in Millions : 172
2018 Revenue in Millions : 469
Growth (%) : -63
Main Therapeutic Indication : Hormonal Disorders
Currency : USD
2014 Revenue in Millions : -9.80%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Endocrinology
Currency : USD
2022 Revenue in Millions : 39
2021 Revenue in Millions : 44
Growth (%) : -11
Main Therapeutic Indication : Endocrinology
Currency : USD
2023 Revenue in Millions : 42
2022 Revenue in Millions : 39
Growth (%) : 10
Main Therapeutic Indication : Harmonal Disorders
Currency : USD
2015 Revenue in Millions : 171
2014 Revenue in Millions : 155
Growth (%) : -9%
Main Therapeutic Indication : Hormonal Disorders
Currency : USD
2016 Revenue in Millions : 145
2015 Revenue in Millions : 155
Growth (%) : -6
LOOKING FOR A SUPPLIER?